Products

Targeted portfolio

A unique portfolio of high quality and difficult-to-make pharmaceutical products fuels our targeted growth strategy. Alvogen has over 200 strategically selected pharmaceutical projects in development and registrations and over 350 marketed products.

More

Company

Who we are

Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, OTC and biosimilar products around the world. The company has commercial operations in 35 countries with 2,800 employees.

More

Newsroom

Alvogen First to Market with Generic Equivalent to Tamiflu® Powder for Oral Suspension

Alvogen is first to market and has received final approval for the generic equivalent to Tamiflu® (oseltamivir phosphate) 6 mg/ml powder for oral suspension in the U.S.

Read More

Meet management

Leadership team

Alvogen’s leadership team is dedicated to fostering a dynamic change-driven culture committed to meeting the needs of our customers. Our organizational structure is lean and flexible, driving quick and effective decision making and thus enabling the company to bring new generic products quickly and safely to market.

Meet management